Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
MRx0518 Capsules
4D Molecular Therapeutics
Melanoma
1 trial -
MSC-derived exosomes
Regeneron Ireland Designated Activity Company (DAC)
Long COVID-19 Syndrome
1 trial -
MSD-001
Lxo Ireland Designated Activity Company
Mental Health Disorders
1 trial -
Nezulcitinib (TD-0903) Dose A
Theravance Biopharma Ireland Umited
Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)
1 trial -
Nivolumab
Bristol-Myers Squibb
Melanoma
1 trial -
Nivolumab
Iovance Biotherapeutics B.V.
Melanoma (Skin)
1 trial -
Nivolumab
Jazz Pharmaceuticals Ireland Limited
Small-cell Lung Cancer
1 trial -
Novel restraint
Lxo Ireland Designated Activity Company
Acute Respiratory Failure
1 trial -
ODSH
Jazz Pharmaceuticals Ireland Limited
Acute Myeloid Leukemia
1 trial -
ODSH at 0.125 mg/kg/h
Jazz Pharmaceuticals Ireland Limited
Protein Losing Enteropathy
1 trial -
ONC206
Jazz Pharmaceuticals Ireland Limited
Diffuse Midline Glioma (DMG)
1 trial -
ONC206
Jazz Pharmaceuticals Ireland Limited
Central Nervous System Neoplasms
1 trial -
PV-10 (rose bengal disodium, 10%)
PROVECTUS BIOPHARMACEUTICALS, INC.
Melanoma
1 trial -
Paclitaxel
Jazz Pharmaceuticals Ireland Limited
Ovarian Cancer
1 trial -
Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Amgen
Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.
1 trial -
Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers
Immunocore Ireland Limited
Advanced PRAME Positive Cancers
1 trial -
Placebo
Jazz Pharmaceuticals Ireland Limited
Epilepsy
1 trial -
Placebo for antibiotic
Seres Therapeutics
Metastatic Melanoma
1 trial -
Placebo spray and oral moxifloxacin placebo
Jazz Pharmaceuticals Ireland Limited
Effects of Sativex on ECG
1 trial -
Pluvicto 1 000 MBq/mL solution for injection/infusion, Lutetium (177Lu) rhPSMA-10.1 injection
Blue Earth Diagnostics Ireland Ltd
PSMA-positive non-curative metastatic castration-resistant prostate cancer
1 trial -
RBL001/RBL002
Atrium Therapeutics
Melanoma
1 trial -
REGN2810
Regeneron UK Limited
Melanoma
1 trial -
Relative bioavailability and safety study of pasireotide after a single-dose subcutaneous administration in the arm or in the thigh compared to in the abdomen using a ServoPen in healthy subjects.
Recordati Ireland
Post-bariatric hypoglycaemia
1 trial -
SKY0402
Pacira Ireland Limited
Postoperative Pain Management
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources